Screener
Denali Therapeutics Inc. DNLI Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $204.64M+41.8% | $390.73M+551% | $208.43M+18.1% | $94.07M+2.0% | $144.31M+89.3% | ||
| $508.94M-32.8% | $600.06M-21.1% | $662.55M+0.8% | $757.24M+1.5% | $757.75M-7.7% | ||
| $3.93M— | —— | $0— | —— | —— | ||
| $4.14M— | —— | $0— | —— | —— | ||
| $753.93M-19.3% | $1.02B+16.4% | $900.66M+4.2% | $882.6M+1.6% | $934.71M+0.7% | ||
| $49.93M-15.0% | $51.73M-10.5% | $52.4M-5.1% | $53.73M+5.7% | $58.72M+22.1% | ||
| $35.25M— | $36M— | $0— | —— | —— | ||
| $1.16B-0.7% | $1.27B-0.4% | $1.14B-16.7% | $1.06B-27.4% | $1.17B-22.4% | ||
| $11.81M+8.9% | $40.38M+377% | $505K-95.5% | $6.75M-29.7% | $10.84M-22.2% | ||
| $97K— | $90K— | $83K— | —— | —— | ||
| $90.08M-1.1% | $110.16M+19.9% | $98.35M-3.8% | $90.15M+3.5% | $91.06M+22.2% | ||
| $322.78M+132% | $339.93M+129% | $131.09M-9.3% | $129.42M-4.5% | $139.19M+20.5% | ||
| $1.92M+7.9% | $1.91M+7.6% | $1.89M+6.8% | $1.79M+1.6% | $1.78M+1.5% | ||
| -$2.31B-28.5% | -$2.18B-30.4% | -$2.05B-33.3% | -$1.92B-35.0% | -$1.8B-36.4% | ||
| $835.18M-18.7% | $926.1M-17.5% | $1.01B-17.6% | $926.2M-29.8% | $1.03B-26.0% | ||
| $1.16B-0.7% | $1.27B-0.4% | $1.14B-16.7% | $1.06B-27.4% | $1.17B-22.4% |
FAQ
- What are Denali Therapeutics Inc.'s total assets?
- Denali Therapeutics Inc. (DNLI) holds $1.2B in total assets, down 0.7% year over year.
- How much debt does Denali Therapeutics Inc. have?
- Denali Therapeutics Inc. carries $37.7M in total debt against $835.2M of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does Denali Therapeutics Inc. have?
- Denali Therapeutics Inc. holds $204.6M in cash and equivalents.
- Can Denali Therapeutics Inc. cover its short-term obligations?
- Its current ratio is 8.37 — current assets exceed current liabilities.
- Where does Denali Therapeutics Inc.'s balance sheet data come from?
- Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
